Dorsey Wright & Associates’s Standard BioTools LAB Stock Holding History

Dorsey Wright & Associates’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,290	Closed	-$16K	–	314
2019 Q2	$16K	Buy	1,290 +322	+33%	+$4.1K	﹤0.01%	164
2019 Q1	$13K	Sell	968 -966	-50%	-$10.2K	﹤0.01%	156
2018 Q4	$17K	Buy	+1,934	New	+$15.1K	0.01%	158

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Dorsey Wright & Associates's LAB Position: Q3 2019 in Review

Dorsey Wright & Associates sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 1,290 shares — an estimated $16K sold.

Dorsey Wright & Associates first reported a position in LAB in Q4 2018 and held it in 3 quarters. The position peaked at $17K in Q4 2018. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

Dorsey Wright & Associates reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
Dorsey Wright & Associates sold 1,290 Standard BioTools shares in Q3 2019, an estimated $16K.
Dorsey Wright & Associates first reported a position in Standard BioTools in Q4 2018 and held it in 3 quarters.
Dorsey Wright & Associates's Standard BioTools position peaked at $17K in Q4 2018.
125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Dorsey Wright & Associates's 13F filing for Q3 2019, filed 31 Oct 2019.